🔎 Trials Near Me

Akèy › Leksemi biphenotipik egi › Washington

Etid klinik pou Leksemi biphenotipik egi nan Washington

15 etid pou Leksemi biphenotipik egi ap chèche patisipan nan sit nan Washington.

Vil nan Washington

Tèks ofisyèl etid la (Anglè)

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  • Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1
Laj 12 a 78 · Tout sèks · Mizajou Sep 29, 2026 · NCT03802695

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Seattle Children's Hospital, Seattle
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
Ap rekriteFaz 2
365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662

Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07094750

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Seattle Children's Hospital, Seattle
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
  • Mary Bridge Children's Hospital and Health Center, Tacoma
Ap rekriteFaz 3
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Seattle Children's Hospital, Seattle
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
  • Mary Bridge Children's Hospital and Health Center, Tacoma
  • ak 1 plis
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 2
6 Months – 65 Years · Tout sèks · Mizajou Jul 22, 2026 · NCT06013423

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jun 22, 2026 · NCT03128034

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jun 22, 2026 · NCT03670966

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 2Volontè an sante akeyi
6 Months · Tout sèks · Mizajou May 29, 2026 · NCT04195633

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 1
Jiska laj 80 · Tout sèks · Mizajou May 18, 2026 · NCT03326921

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou May 15, 2026 · NCT06928662

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 17, 2026 · NCT04797767

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Seattle Children's Hospital, Seattle
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770

Sous ClinicalTrials.gov, done yo ranmase Oct 3, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.